Kim Blickenstaff - Tandem Diabetes Insider

Tandem Diabetes Care -- USA Stock  

USD 7.09  0.28  3.80%

CEO and President and Director

Mr. Kim D. Blickenstaff is President, Chief Executive Officer, and Director of Tandem Diabetes Care, Inc. Prior to joining our company, he served as Chairman and Chief Executive Officer of Biosite Incorporated, or Biosite, a provider of medical diagnostic products, from 1988 until its acquisition by Inverness Medical Innovations, Inc. in June 2007. Mr. Blickenstaff currently serves as Chairman of Medivation, Inc., and is a member of its audit committee. He previously served as a director of DexCom, Inc., a provider of glucose monitoring systems, from June 2001 to September 2007
Age: 63  CEO Since 2007  MBA    
858-366-6900  http://www.tandemdiabetes.com
Blickenstaff was formerly a certified public accountant and has more than 20 years of experience overseeing the preparation of financial statements. He received a B.A. in Political Science from Loyola University, Chicago, and an M.B.A. from the Graduate School of Business, Loyola University, Chicago.

Kim Blickenstaff Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (37.87) % which means that it has lost $37.87 on every $100 spent on asset. This is way below average.
The company currently holds 76.54 M in liabilities with Debt to Equity (D/E) ratio of 8.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Tandem Diabetes Care has Current Ratio of 1.74 which is within standard range for the sector.

Similar Executives

Found 1 records

CEO Since

Kevin SayerDexCom
2015

Entity Summary

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California. Tandem Diabetes operates under Medical Devices classification in USA and traded on NASDAQ General Markets. It employs 574 people.Tandem Diabetes Care (TNDM) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 574 people. Tandem Diabetes is listed under Medical Equipment category by Fama And French industry classification.

Tandem Diabetes Care Leadership Team

Brian Hansen, President, MBA
Fred Cohen, Director
Susan Morrison, Executive
Lori Gildea, President, MBA
Howard Greene, Director, MBA
Christopher Twomey, Director
Henry Anhalt, Director
Edward Cahill, Director
Lonnie Smith, Chairman, MBA
John Cajigas, CFO
Dick Allen, Chairman, MBA
David Berger, Executive
Jesse Treu, Director, Ph.D
Douglas Roeder, Director
Leigh Vosseller, President
John Sheridan, COO, MBA
Kim Blickenstaff, CEO, MBA
Robert Anacone, EVP

Stock Performance Indicators

Current Sentiment - TNDM

Tandem Diabetes Care Investor Sentiment
Most of Macroaxis users are at this time bullish on Tandem Diabetes Care. What is your outlook on investing in Tandem Diabetes Care? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Trending Equities

Currently Active Assets on Macroaxis
V   
 NYQ 
Sold over 20 shares of
3 hours ago
Traded for 124.2
CRM   
 NYQ 
Purchased over 20 shares of
3 hours ago
Traded for 122.82
MSFT   
 NMS 
Purchased over 30 shares of
3 hours ago
Traded for 95.0
C   
 NYQ 
Purchased over 40 shares of
3 hours ago
Traded for 70.0
TWTR   
 NYQ 
Purchased over 90 shares of
3 hours ago
Traded for 31.91
GM   
 NYQ 
Purchased over 70 shares of
3 hours ago
Traded for 37.61
Also please take a look at World Market Map. Please also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.